The Parkinson Progression Marker Initiative (PPMI)

Keywords

Parkinson's disease, Medicine, Biomarker, Clinical trial, Neuroscience

References

• Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.Donald A. Norman, Jim Spohrer — 2010
• Levodopa and the progression of Parkinson's disease.The Parkinson Study Group — 2004
• The role of the core imaging laboratory in multicenter trials.John Seibyl, Kenneth Marek, I. George Zubal — 2010
• CSF amyloid β 1-42 predicts cognitive decline in Parkinson diseaseAndrew Siderowf, Sharon X. Xie, Howard I. Hurtig — 2010
• Lower body (vascular) parkinsonism.Joseph Jankovic — 1990
• Neurochemical biomarkers in the differential diagnosis of movement disordersBrit Mollenhauer, Claudia Trenkwalder — 2009
• Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET studyAlan Whone, Ray L. Watts, A. Jon Stoessl — 2003
• Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendationsCarlo Colosimo, Pablo Martínez‐Martín, Giovanni Fabbrini — 2010
• The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plansMichael W. Weiner, Paul Aisen, Clifford R. Jack — 2010
• Striatonigral degeneration. A clinicopathological study.Julian Fearnley, Andrew J. Lees — 1990
• Cerebrospinal Fluid Biomarker Signature in Alzheimer’s Disease Neuroimaging Initiative SubjectsLeslie M. Shaw, Hugo Vanderstichele, Małgorzata Knapik-Czajka — 2009
• Clinical core of the Alzheimer's Disease Neuroimaging Initiative: progress and plansPaul Aisen, Ronald C. Petersen, Michael Donohue — 2010
• Biomarker Discovery in Neurodegenerative Diseases: A Proteomic ApproachMin Shi, W. Michael Caudle, Jing Zhang — 2008
• CSF Aβ42 and tau in Parkinson’s disease with cognitive impairmentNorbert Brüggemann, Susanne A. Schneider, Thurid Sander — 2010
• The Alzheimer's Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardMark E. Schmidt, Eric Siemers, Peter J. Snyder — 2010
• Update on the Biomarker Core of the Alzheimer's Disease Neuroimaging Initiative SubjectsJohn Q. Trojanowski, Hugo Vandeerstichele, Magdalena Korecka — 2010
• Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorderChristine Klein, Michael G. Schlossmacher — 2007
• A longitudinal program for biomarker development in Parkinson's disease: A feasibility studyBernard Ravina, Caroline M. Tanner, Diane DiEuliis — 2009
• Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD studyAnthony H.V. Schapira, Stefan Albrecht, Paolo Barone — 2010
• TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.C. Warren Olanow, Anthony H.V. Schapira, Peter A. LeWitt — 2006

Cited by

• Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's diseaseLorenzo Tosi — 2015
• Altered resting‐state functional connectivity of the putamen and internal globus pallidus is related to speech impairment in Parkinson's diseaseJordan L. Manes, Kris Tjaden, Todd B. Parrish — 2018
• Autonomic dysfunction and white matter microstructural changes in drug-naïve patients with Parkinson’s disease山崎義弘 — 2018
• REM sleep behavior disorder predicts functional dependency in early Parkinson's disease.彭应翃, 杨锋 — 2019
• Biomarkers in Parkinson's disease: an update.Alexander Shtilbans, Claire Henchcliffe — 2012
• The Image and Data Archive at the Laboratory of Neuro ImagingKaren Crawford, Scott Neu, Arthur W. Toga — 2015
• Mitigating Oxidative Stress in Childhood Cerebral Adrenoleukodystrophy -An Investigation of N-acetylcysteine PharmacologyJie Zhou — 2014
• Patterns of motor and non-motor features in medication-naïve ParkinsonismSamay Jain, Seo‐Young Park, Diane Comer — 2015
• Quantitative wearable sensors for objective assessment of Parkinson's diseaseWalter Maetzler, Josefa Domingos, Karin Srulijes — 2013
• Early detection of Parkinson's disease through shape based features from 123I-Ioflupane SPECT imagingNoopur A. Bhalchandra, R. Prashanth, Sumantra Dutta Roy — 2015
• Biomarkers for trials of neuroprotection in Parkinson's diseasePankaj Agarwal, A. Jon Stoessl — 2013
• Plasma Apolipoprotein A1 as a Biomarker for Parkinson's DiseaseJudy Qiang, Yvette C. Wong, Andrew Siderowf — 2013
• The Global Alzheimer’s Association Interactive NetworkArthur W. Toga, Scott Neu, Priya Bhatt — 2015
• Planning for selective amygdalohippocampectomy involving less neuronal fiber damage based on brain connectivity using tractographyHyunjin Park, Seung-Hak Lee, Mansu Kim — 2015
• Cognitive Performance and Neuropsychiatric Symptoms in Early, Untreated Parkinson’s DiseaseDaniel Weintraub, Tanya Simuni, Chelsea Caspell‐Garcia — 2015
• Linked Clinical Trials – The Development of New Clinical Learning Studies in Parkinson’s Disease Using Screening of Multiple Prospective New TreatmentsPatrik Brundin, Roger A. Barker, P. Jeffrey Conn — 2013
• Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)Mike A. Nalls, Margaux F. Keller, Dena Hernández — 2015
• Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's DiseaseMalco Rossi, Santiago Perez‐Lloret, Patricio Millar Vernetti — 2015
• Diffusion Tensor Imaging of the Nigrostriatal Fibers in Parkinson’s DiseaseYu Zhang, I‐Wei Wu, Shannon Buckley — 2015
• Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB)Enchi Liu, Johan Luthman, Jesse M. Cedarbaum — 2015

Related papers

• P4‐123: Resolving Conflicting CSF Biomarker Information in Alzheimer′s DiseaseKelly D. Watts, J. Christina Howell, Patricia Herrera — 2016
• Usefulness of Parkinson's KinetiGraph in a Parkinson's disease clinic – Survey of 82 patientsLisa Klingelhoefer, Alexandra Rizos, Anna Sauerbier — 2016
• Supporting evidence for using biomarkers in the diagnosis of MCI due to ADSamantha Galluzzi, Cristina Geroldi, Giovanni Amicucci — 2013
• Subthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trialCarlo Alberto Artusi, Claudia Ledda, Silvia Gallo — 2024
• P2‐215: Supporting evidence of the Alzheimer's disease biomarker dynamic model in patients with mild cognitive impairmentSamantha Galluzzi, Cristina Geroldi, Giovanni Amicucci — 2012
• 薬剤性Parkinson症候群 (7月第1土曜特集 Parkinson病) -- (Parkinson症候群)茂樹 葛原 — 1998
• Resonance Raman Spectroscopic Evaluation of Skin Carotenoids as a Biomarker of Carotenoid Status for Human StudiesSusan T. Mayne, Brenda Cartmel, Stephanie Scarmo — 2013
• Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: Post hoc Analysesof Studies 016 and SETTLEC. Cattaneo, Marco Sardina, Ermino Bonizzoni — 2016
• P.1.c.001 An ethopharmacological assessment of the effects of (R, S)-2-chloro-5-hydroxyphenylglycine (CHPG) on agonistic interactions in male micePedro E. Huertas, Mercedes Martín‐López, Estrella Burón — 2008